Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
The biology of cancer as well as potential treatment options are examined by experts.
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Higher levels of HIF2α found to slow down aggressive childhood cancer
4.
Universal screening approach achieves a comparable detection rate of lung cancer
5.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
1.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
2.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
3.
AI in Cancer Diagnostics and Imaging Interpretation
4.
Optimizing the Diagnosis and Treatment of Hematological Diseases Through Artificial Intelligence
5.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge